Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease
Identifieur interne : 002525 ( Main/Corpus ); précédent : 002524; suivant : 002526Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease
Auteurs : Toshitaka Nakamura ; Vijay Dhawan ; Thomas Chaly ; Masafumi Fukuda ; Yilong Ma ; Robert Breeze ; Paul Greene ; Stanley Fahn ; Curt Freed ; David EidelbergSource :
- Annals of Neurology [ 0364-5134 ] ; 2001-08.
Abstract
We assessed nigrostriatal dopaminergic function in Parkinson's disease (PD) patients undergoing a double‐blind, placebo‐controlled surgical trial of embryonic dopamine cell implantation. Forty PD patients underwent positron emission tomography (PET) imaging with [18F]fluorodopa (FDOPA) prior to randomization to transplantation or placebo surgery. The 39 surviving patients were rescanned 1 year following surgery. Images were quantified by investigators blinded to treatment status and clinical outcome. Following unblinding, we determined the effects of treatment status and age on the interval changes in FDOPA/PET signal. Blinded observers detected a significant increase in FDOPA uptake in the putamen of the group receiving implants compared to the placebo surgery patients (40.3%). Increases in putamen FDOPA uptake were similar in both younger (age ≤60 years) and older (age >60 years) transplant recipients. Significant decrements in putamen uptake were evident in younger placebo‐operated patients (–6.5% ) but not in their older counterparts. Correlations between the PET changes and clinical outcome were significant only in the younger patient subgroup (r = 0.58). The findings suggest that patient age does not influence graft viability or development in the first postoperative year. However, host age may influence the time course of the downstream functional changes that are needed for clinical benefit to occur.
Url:
DOI: 10.1002/ana.1075
Links to Exploration step
ISTEX:BD1747D2C4B8972C8C7D4BCAC315D671D29D7418Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease</title><author><name sortKey="Nakamura, Toshitaka" sort="Nakamura, Toshitaka" uniqKey="Nakamura T" first="Toshitaka" last="Nakamura">Toshitaka Nakamura</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author><author><name sortKey="Dhawan, Vijay" sort="Dhawan, Vijay" uniqKey="Dhawan V" first="Vijay" last="Dhawan">Vijay Dhawan</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author><author><name sortKey="Chaly, Thomas" sort="Chaly, Thomas" uniqKey="Chaly T" first="Thomas" last="Chaly">Thomas Chaly</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author><author><name sortKey="Fukuda, Masafumi" sort="Fukuda, Masafumi" uniqKey="Fukuda M" first="Masafumi" last="Fukuda">Masafumi Fukuda</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author><author><name sortKey="Ma, Yilong" sort="Ma, Yilong" uniqKey="Ma Y" first="Yilong" last="Ma">Yilong Ma</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author><author><name sortKey="Breeze, Robert" sort="Breeze, Robert" uniqKey="Breeze R" first="Robert" last="Breeze">Robert Breeze</name><affiliation><mods:affiliation>Department of Neurology, Columbia College of Physicians and Surgeons, New York, NY</mods:affiliation></affiliation></author><author><name sortKey="Greene, Paul" sort="Greene, Paul" uniqKey="Greene P" first="Paul" last="Greene">Paul Greene</name><affiliation><mods:affiliation>Department of Neurosurgery and</mods:affiliation></affiliation></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation><mods:affiliation>Department of Neurosurgery and</mods:affiliation></affiliation></author><author><name sortKey="Freed, Curt" sort="Freed, Curt" uniqKey="Freed C" first="Curt" last="Freed">Curt Freed</name><affiliation><mods:affiliation>Neuroscience Center and Division of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver, CO</mods:affiliation></affiliation></author><author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BD1747D2C4B8972C8C7D4BCAC315D671D29D7418</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/ana.1075</idno><idno type="url">https://api.istex.fr/document/BD1747D2C4B8972C8C7D4BCAC315D671D29D7418/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002525</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease</title><author><name sortKey="Nakamura, Toshitaka" sort="Nakamura, Toshitaka" uniqKey="Nakamura T" first="Toshitaka" last="Nakamura">Toshitaka Nakamura</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author><author><name sortKey="Dhawan, Vijay" sort="Dhawan, Vijay" uniqKey="Dhawan V" first="Vijay" last="Dhawan">Vijay Dhawan</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author><author><name sortKey="Chaly, Thomas" sort="Chaly, Thomas" uniqKey="Chaly T" first="Thomas" last="Chaly">Thomas Chaly</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author><author><name sortKey="Fukuda, Masafumi" sort="Fukuda, Masafumi" uniqKey="Fukuda M" first="Masafumi" last="Fukuda">Masafumi Fukuda</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author><author><name sortKey="Ma, Yilong" sort="Ma, Yilong" uniqKey="Ma Y" first="Yilong" last="Ma">Yilong Ma</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author><author><name sortKey="Breeze, Robert" sort="Breeze, Robert" uniqKey="Breeze R" first="Robert" last="Breeze">Robert Breeze</name><affiliation><mods:affiliation>Department of Neurology, Columbia College of Physicians and Surgeons, New York, NY</mods:affiliation></affiliation></author><author><name sortKey="Greene, Paul" sort="Greene, Paul" uniqKey="Greene P" first="Paul" last="Greene">Paul Greene</name><affiliation><mods:affiliation>Department of Neurosurgery and</mods:affiliation></affiliation></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation><mods:affiliation>Department of Neurosurgery and</mods:affiliation></affiliation></author><author><name sortKey="Freed, Curt" sort="Freed, Curt" uniqKey="Freed C" first="Curt" last="Freed">Curt Freed</name><affiliation><mods:affiliation>Neuroscience Center and Division of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver, CO</mods:affiliation></affiliation></author><author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name><affiliation><mods:affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, New York University School of Medicine</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-08">2001-08</date><biblScope unit="volume">50</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="181">181</biblScope><biblScope unit="page" to="187">187</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">BD1747D2C4B8972C8C7D4BCAC315D671D29D7418</idno><idno type="DOI">10.1002/ana.1075</idno><idno type="ArticleID">ANA1075</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We assessed nigrostriatal dopaminergic function in Parkinson's disease (PD) patients undergoing a double‐blind, placebo‐controlled surgical trial of embryonic dopamine cell implantation. Forty PD patients underwent positron emission tomography (PET) imaging with [18F]fluorodopa (FDOPA) prior to randomization to transplantation or placebo surgery. The 39 surviving patients were rescanned 1 year following surgery. Images were quantified by investigators blinded to treatment status and clinical outcome. Following unblinding, we determined the effects of treatment status and age on the interval changes in FDOPA/PET signal. Blinded observers detected a significant increase in FDOPA uptake in the putamen of the group receiving implants compared to the placebo surgery patients (40.3%). Increases in putamen FDOPA uptake were similar in both younger (age ≤60 years) and older (age >60 years) transplant recipients. Significant decrements in putamen uptake were evident in younger placebo‐operated patients (–6.5% ) but not in their older counterparts. Correlations between the PET changes and clinical outcome were significant only in the younger patient subgroup (r = 0.58). The findings suggest that patient age does not influence graft viability or development in the first postoperative year. However, host age may influence the time course of the downstream functional changes that are needed for clinical benefit to occur.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Toshitaka Nakamura MD</name><affiliations><json:string>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</json:string><json:string>Department of Neurology, New York University School of Medicine</json:string></affiliations></json:item><json:item><name>Vijay Dhawan PhD</name><affiliations><json:string>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</json:string><json:string>Department of Neurology, New York University School of Medicine</json:string></affiliations></json:item><json:item><name>Thomas Chaly PhD</name><affiliations><json:string>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</json:string><json:string>Department of Neurology, New York University School of Medicine</json:string></affiliations></json:item><json:item><name>Masafumi Fukuda MD</name><affiliations><json:string>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</json:string><json:string>Department of Neurology, New York University School of Medicine</json:string></affiliations></json:item><json:item><name>Yilong Ma PhD</name><affiliations><json:string>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</json:string><json:string>Department of Neurology, New York University School of Medicine</json:string></affiliations></json:item><json:item><name>Robert Breeze MD</name><affiliations><json:string>Department of Neurology, Columbia College of Physicians and Surgeons, New York, NY</json:string></affiliations></json:item><json:item><name>Paul Greene MD</name><affiliations><json:string>Department of Neurosurgery and</json:string></affiliations></json:item><json:item><name>Stanley Fahn MD</name><affiliations><json:string>Department of Neurosurgery and</json:string></affiliations></json:item><json:item><name>Curt Freed MD</name><affiliations><json:string>Neuroscience Center and Division of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver, CO</json:string></affiliations></json:item><json:item><name>David Eidelberg MD</name><affiliations><json:string>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</json:string><json:string>Department of Neurology, New York University School of Medicine</json:string></affiliations></json:item></author><articleId><json:string>ANA1075</json:string></articleId><language><json:string>eng</json:string></language><abstract>We assessed nigrostriatal dopaminergic function in Parkinson's disease (PD) patients undergoing a double‐blind, placebo‐controlled surgical trial of embryonic dopamine cell implantation. Forty PD patients underwent positron emission tomography (PET) imaging with [18F]fluorodopa (FDOPA) prior to randomization to transplantation or placebo surgery. The 39 surviving patients were rescanned 1 year following surgery. Images were quantified by investigators blinded to treatment status and clinical outcome. Following unblinding, we determined the effects of treatment status and age on the interval changes in FDOPA/PET signal. Blinded observers detected a significant increase in FDOPA uptake in the putamen of the group receiving implants compared to the placebo surgery patients (40.3%). Increases in putamen FDOPA uptake were similar in both younger (age ≤60 years) and older (age >60 years) transplant recipients. Significant decrements in putamen uptake were evident in younger placebo‐operated patients (–6.5% ) but not in their older counterparts. Correlations between the PET changes and clinical outcome were significant only in the younger patient subgroup (r = 0.58). The findings suggest that patient age does not influence graft viability or development in the first postoperative year. However, host age may influence the time course of the downstream functional changes that are needed for clinical benefit to occur.</abstract><qualityIndicators><score>7.245</score><pdfVersion>1.2</pdfVersion><pdfPageSize>603 x 783 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1431</abstractCharCount><pdfWordCount>4821</pdfWordCount><pdfCharCount>30197</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>202</abstractWordCount></qualityIndicators><title>Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>50</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>7</total><last>187</last><first>181</first></pages><issn><json:string>0364-5134</json:string></issn><issue>2</issue><subject><json:item><value>Original Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1002/ana.1075</json:string></doi><id>BD1747D2C4B8972C8C7D4BCAC315D671D29D7418</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/BD1747D2C4B8972C8C7D4BCAC315D671D29D7418/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/BD1747D2C4B8972C8C7D4BCAC315D671D29D7418/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/BD1747D2C4B8972C8C7D4BCAC315D671D29D7418/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>WILEY</p></availability><date>2001</date></publicationStmt><notesStmt><note>NIH - No. RO1 NS 32368; No. RO1 NS 35069;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease</title><author><persName><forename type="first">Toshitaka</forename><surname>Nakamura</surname></persName><roleName type="degree">MD</roleName><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation></author><author><persName><forename type="first">Vijay</forename><surname>Dhawan</surname></persName><roleName type="degree">PhD</roleName><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation></author><author><persName><forename type="first">Thomas</forename><surname>Chaly</surname></persName><roleName type="degree">PhD</roleName><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation></author><author><persName><forename type="first">Masafumi</forename><surname>Fukuda</surname></persName><roleName type="degree">MD</roleName><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation></author><author><persName><forename type="first">Yilong</forename><surname>Ma</surname></persName><roleName type="degree">PhD</roleName><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation></author><author><persName><forename type="first">Robert</forename><surname>Breeze</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Columbia College of Physicians and Surgeons, New York, NY</affiliation></author><author><persName><forename type="first">Paul</forename><surname>Greene</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurosurgery and</affiliation></author><author><persName><forename type="first">Stanley</forename><surname>Fahn</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurosurgery and</affiliation></author><author><persName><forename type="first">Curt</forename><surname>Freed</surname></persName><roleName type="degree">MD</roleName><affiliation>Neuroscience Center and Division of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver, CO</affiliation></author><author><persName><forename type="first">David</forename><surname>Eidelberg</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, 350 Community Drive, Manhasset, NY 11030</p></note><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-08"></date><biblScope unit="volume">50</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="181">181</biblScope><biblScope unit="page" to="187">187</biblScope></imprint></monogr><idno type="istex">BD1747D2C4B8972C8C7D4BCAC315D671D29D7418</idno><idno type="DOI">10.1002/ana.1075</idno><idno type="ArticleID">ANA1075</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We assessed nigrostriatal dopaminergic function in Parkinson's disease (PD) patients undergoing a double‐blind, placebo‐controlled surgical trial of embryonic dopamine cell implantation. Forty PD patients underwent positron emission tomography (PET) imaging with [18F]fluorodopa (FDOPA) prior to randomization to transplantation or placebo surgery. The 39 surviving patients were rescanned 1 year following surgery. Images were quantified by investigators blinded to treatment status and clinical outcome. Following unblinding, we determined the effects of treatment status and age on the interval changes in FDOPA/PET signal. Blinded observers detected a significant increase in FDOPA uptake in the putamen of the group receiving implants compared to the placebo surgery patients (40.3%). Increases in putamen FDOPA uptake were similar in both younger (age ≤60 years) and older (age >60 years) transplant recipients. Significant decrements in putamen uptake were evident in younger placebo‐operated patients (–6.5% ) but not in their older counterparts. Correlations between the PET changes and clinical outcome were significant only in the younger patient subgroup (r = 0.58). The findings suggest that patient age does not influence graft viability or development in the first postoperative year. However, host age may influence the time course of the downstream functional changes that are needed for clinical benefit to occur.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Original Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2000-12-06">Received</change><change when="2001-03-27">Registration</change><change when="2001-08">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/BD1747D2C4B8972C8C7D4BCAC315D671D29D7418/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/ana.v50:2</doi><numberingGroup><numbering type="journalVolume" number="50">50</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2001-08">August 2001</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="70" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.1075</doi><idGroup><id type="unit" value="ANA1075"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Original Article</title><title type="tocHeading1">Original Articles</title></titleGroup><copyright ownership="publisher">Copyright © 2001 Wiley‐Liss, Inc.</copyright><eventGroup><event type="manuscriptReceived" date="2000-12-06"></event><event type="manuscriptRevised" date="2001-03-27"></event><event type="manuscriptAccepted" date="2001-03-27"></event><event type="firstOnline" date="2001-05-16"></event><event type="publishedOnlineFinalForm" date="2001-07-30"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2001-05-16"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">181</numbering><numbering type="pageLast">187</numbering></numberingGroup><correspondenceTo>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, 350 Community Drive, Manhasset, NY 11030</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA1075.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="4"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="30"></count><count type="wordTotal" number="5496"></count></countGroup><titleGroup><title type="main" xml:lang="en">Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease</title><title type="short" xml:lang="en">PET in Implantation for PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Toshitaka</givenNames><familyName>Nakamura</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Vijay</givenNames><familyName>Dhawan</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Thomas</givenNames><familyName>Chaly</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Masafumi</givenNames><familyName>Fukuda</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Yilong</givenNames><familyName>Ma</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Robert</givenNames><familyName>Breeze</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Paul</givenNames><familyName>Greene</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Stanley</givenNames><familyName>Fahn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Curt</givenNames><familyName>Freed</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>David</givenNames><familyName>Eidelberg</familyName><degrees>MD</degrees></personName><contactDetails><email>david1@nshs.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, New York University School of Medicine</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Columbia College of Physicians and Surgeons, New York, NY</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurosurgery and</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Neuroscience Center and Division of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver, CO</unparsedAffiliation></affiliation></affiliationGroup><fundingInfo><fundingAgency>NIH</fundingAgency><fundingNumber>RO1 NS 32368</fundingNumber><fundingNumber>RO1 NS 35069</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We assessed nigrostriatal dopaminergic function in Parkinson's disease (PD) patients undergoing a double‐blind, placebo‐controlled surgical trial of embryonic dopamine cell implantation. Forty PD patients underwent positron emission tomography (PET) imaging with [<sup>18</sup>F]fluorodopa (FDOPA) prior to randomization to transplantation or placebo surgery. The 39 surviving patients were rescanned 1 year following surgery. Images were quantified by investigators blinded to treatment status and clinical outcome. Following unblinding, we determined the effects of treatment status and age on the interval changes in FDOPA/PET signal. Blinded observers detected a significant increase in FDOPA uptake in the putamen of the group receiving implants compared to the placebo surgery patients (40.3%). Increases in putamen FDOPA uptake were similar in both younger (age ≤60 years) and older (age >60 years) transplant recipients. Significant decrements in putamen uptake were evident in younger placebo‐operated patients (–6.5% ) but not in their older counterparts. Correlations between the PET changes and clinical outcome were significant only in the younger patient subgroup (<i>r</i> = 0.58). The findings suggest that patient age does not influence graft viability or development in the first postoperative year. However, host age may influence the time course of the downstream functional changes that are needed for clinical benefit to occur.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>PET in Implantation for PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Toshitaka</namePart><namePart type="family">Nakamura</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vijay</namePart><namePart type="family">Dhawan</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas</namePart><namePart type="family">Chaly</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Masafumi</namePart><namePart type="family">Fukuda</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yilong</namePart><namePart type="family">Ma</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert</namePart><namePart type="family">Breeze</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Columbia College of Physicians and Surgeons, New York, NY</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paul</namePart><namePart type="family">Greene</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurosurgery and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stanley</namePart><namePart type="family">Fahn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurosurgery and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Curt</namePart><namePart type="family">Freed</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neuroscience Center and Division of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver, CO</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Eidelberg</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, Manhasset, NY</affiliation><affiliation>Department of Neurology, New York University School of Medicine</affiliation><description>Correspondence: Functional Brain Imaging Laboratory, North Shore‐Long Island Jewish Research Institute, 350 Community Drive, Manhasset, NY 11030</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2001-08</dateIssued><dateCaptured encoding="w3cdtf">2000-12-06</dateCaptured><dateValid encoding="w3cdtf">2001-03-27</dateValid><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">4</extent><extent unit="tables">2</extent><extent unit="references">30</extent><extent unit="words">5496</extent></physicalDescription><abstract lang="en">We assessed nigrostriatal dopaminergic function in Parkinson's disease (PD) patients undergoing a double‐blind, placebo‐controlled surgical trial of embryonic dopamine cell implantation. Forty PD patients underwent positron emission tomography (PET) imaging with [18F]fluorodopa (FDOPA) prior to randomization to transplantation or placebo surgery. The 39 surviving patients were rescanned 1 year following surgery. Images were quantified by investigators blinded to treatment status and clinical outcome. Following unblinding, we determined the effects of treatment status and age on the interval changes in FDOPA/PET signal. Blinded observers detected a significant increase in FDOPA uptake in the putamen of the group receiving implants compared to the placebo surgery patients (40.3%). Increases in putamen FDOPA uptake were similar in both younger (age ≤60 years) and older (age >60 years) transplant recipients. Significant decrements in putamen uptake were evident in younger placebo‐operated patients (–6.5% ) but not in their older counterparts. Correlations between the PET changes and clinical outcome were significant only in the younger patient subgroup (r = 0.58). The findings suggest that patient age does not influence graft viability or development in the first postoperative year. However, host age may influence the time course of the downstream functional changes that are needed for clinical benefit to occur.</abstract><note type="funding">NIH - No. RO1 NS 32368; No. RO1 NS 35069; </note><relatedItem type="host"><titleInfo><title>Annals of Neurology</title></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Original Article</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>181</start><end>187</end><total>7</total></extent></part></relatedItem><identifier type="istex">BD1747D2C4B8972C8C7D4BCAC315D671D29D7418</identifier><identifier type="DOI">10.1002/ana.1075</identifier><identifier type="ArticleID">ANA1075</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2001 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>John Wiley & Sons, Inc.</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002525 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002525 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:BD1747D2C4B8972C8C7D4BCAC315D671D29D7418
|texte= Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |